Alzheimers Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Alzheimers Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Alzheimer’s Drugs Market

The Alzheimer’s drugs market size was valued at USD 3.52 billion in 2022, and the market is now projected to grow from USD 3.69 billion in 2023 to USD 5.21 billion by 2030, exhibiting a CAGR of 5.1% during the forecast period of 2023-2030.

The COVID-19 pandemic undesirably impacted the market development, resultant in slower progression. This is majorly due to the dropped occurrence of Alzheimer’s disease (AD) treated patients during 2020 as well as the major impact on the diagnosis and treatment of the disease.

Growing awareness about Alzheimer's disease universally in current years, with more people becoming attentive of the signs and looking for medical consideration. This has led to an upsurge in the diagnosis rates of Alzheimer's disease which in turn encourages the demand for Alzheimer’s drugs used in the trade of Alzheimer's disease and allied dementia. The prominence of early finding and also targets to urge the local establishments and private establishments to donate funds that help in further investigation and caution. Thus, the increasing alertness regarding this ailment and treatment is further growing the practice of Alzheimer’s drugs to identify patients efficiently and is estimated to augment the Alzheimer’s drugs market growth during the prediction period.

Rising patient populace of Alzheimer’s disease, researchers are motivated on the introduction of advanced devices and healings for better understanding, diagnosis, and dealing of the disease. The researchers are using artificial intelligence (AI), virtual reality, as well as machine learning technology to find novel ways to analyze data and speed up medical trials.

Comprehensive Analysis of Alzheimer’s Drugs Market

The market can be segmented in various ways, depending on the focus of analysis such as by drugs class, by distribution channel and by application. Based on drugs class, the market is classified into cholinesterase inhibitors, NMDA receptor antagonist, combination drugs, and others. Based on application, the market is segmented into disease progression and symptom management. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy & drug stores, and online pharmacy.

North America region is dominating the Alzheimer’s drugs market share due to high occurrence of Alzheimer’s ailment, recent new drug supports by governing bodies, and the accessibility of progressive healthcare systems in the region.

The key players are enthusiastically contributing in planned events that are targeted at maintaining durable market position and growing market share by merger, partnerships and others. These players include EISAI CO., LTD. (Japan), Novartis AG (Switzerland), Biogen Inc. (U.S.), H. Lundbeck A/S (Denmark), Otsuka Pharmaceutical Co., Ltd. (Japan) these market players spending severely on research and development in order to arise with more new technology so that they can maintain and improve their existing market.

In December 2022, Eisai Co. Ltd. and Washington University School of Medicine in St. Louis designed a research association to progress novel treatments for Alzheimer’s disease, Parkinson’s disease and other neurodegenerative conditions.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Growth Rate CAGR of 5.1% from 2023-2030

Unit Value (USD Billion)

Segmentation By Drug Class

Cholinesterase Inhibitors

NMDA Receptor Antagonist

Combination Drugs

Others

By Application

Disease Progression

Symptom Management

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy & Drug Stores

Online Pharmacy

By Region

North America (By Drug Class, Application, Distribution Channel, and Country/Sub-Region)

U.S.

Canada

Europe (By Drug Class, Application, Distribution Channel, and Country/Sub-Region)

Germany

U.K.

France

Italy

Spain

Rest of Europe

Asia Pacific (By Drug Class, Application, Distribution Channel, and Country/Sub-Region)

China

Japan

India

Australia

Rest of Asia Pacific

Rest of the World (By Drug Class, Application, Distribution Channel)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.